Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing

... is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer ...

Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing

... is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer ...

ArborGen and Senesco Announce Wood Quality Results

... is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer ...

Senesco Technologies, Inc. Announces the Appointment of Dr. Harlan W. Waksal, M.D. as Chairman of the Board of Directors and the Addition of Mr. Warren J. Isabelle, CFA to its Board of Directors

... is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer ...

Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy

... is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer ...

Senesco Technologies Reports Third Quarter Fiscal 2009 Financial Results

... is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer ...

PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research

... Prevention, anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis . Anthrax most commonly occurs in hoofed mammals and can also infect humans. Symptoms of disease vary depending on how the disease is contracted, but usually occur within seven days after exposure. ...

Chromosome breakpoints contribute to genetic variation

... about what was going on in breakpoints." In the new study, Denis Larkin, a senior scientist on Lewin's team, compared the chromosomes of nine mammals (human, chimp, macaque, rat, mouse, pig, cattle, dog, opossum) and a chicken. He found that the breakpoint regions contained many more copy number ...

Ecologists propose first prevention for white-nose syndrome death in bats

... the idea, suspected by many in the bat research community, that the fungus causes bats to spend more time out of hibernation during the winter. mammals must rouse from hibernation periodically, but doing so too often or for long periods of time is energetically costly. When they rouse, the bats must ...

PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting

... Prevention, anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis . Anthrax most commonly occurs in hoofed mammals and can also infect humans. Symptoms of disease vary depending on how the disease is contracted, but usually occur within seven days after exposure. ...

Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results

... is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer ...

Developing a Safer and More Effective Way to Deliver Rabies Antibodies

... especially in developing countries," said Charles E. Rupprecht, V.M.D., chief of the CDC's Rabies Program. Rabies is a viral disease of mammals which is transmitted through the bite of infected animals. The virus infects the central nervous system, causing inflammation of the brain and ...

Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring

... is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer ...

GEN Reports Growing Focus on PI3-Kinase Pathway in Cancer Research

... the role of PI3-kinase isoforms in normal physiology and disease. A team led by Dr. Bart Vanhaesebroeck isolated the PI3-kinase genes in various mammals and developed models to better understand gene function. Also covered in the GEN article is research taking place at Eli Lilly, the ...

Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors

... is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer ...

Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)

... Prevention, anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in hoofed mammals and can also infect humans. Symptoms of disease vary depending on how the disease is contracted, but usually occur within seven days after exposure. ...

Senesco's Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics'

... is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer ...

Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience

... is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer ...

Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing

... is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer ...

Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System

... is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer ...

Senesco Technologies to Present at BIO 2008 Business Forum

... opportunities of mutual interest. About Senesco Technologies, Inc. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if its technology is applicable in human medicine. Accelerating apoptosis may have applications to the development of cancer ...

Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results

... is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer ...

Senesco Technologies Regains Compliance With Amex's Continued Listing Requirements

... is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer ...

Gladstone scientists identify role of tiny RNAs in controlling stem cell fate

... are active at the early stages of heart cell formation, when an ES cell is first deciding to become mesoderm, one of the three basic tissue layers in mammals and other organisms. Activity of either miR-1 or miR-133 in ES cells caused genes that encourage mesoderm formation to be turned on. Equally ...

Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results

... is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer ...

Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies

... is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer ...

Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing

... is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer ...

Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007

... responses elicited by the lipid-DNA complexes have been successfully demonstrated in both prophylactic and therapeutic settings in a variety of mammals including rodents, rabbits, cats, dogs and non-human primates. This platform provides the opportunity to develop many disease-specific immunotherapy ...

New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces

... hibernation in mice, which was published in a landmark article in the prestigious journal Science. Hibernation may be a latent ability in all mammals -- a finding that may have important clinical benefits in humans. Temporary slowing of the metabolic rate, or inducing hibernation on demand, has the ...

UW-Madison rat experiment could lead to stem-cell treatment for ALS

... given this disease," Klein told WTN. "So basically there's no other model besides the rodent. So one thing that may need to be done is [using] larger mammals just putting in stem cells into the spinal cord of a pig, for example, just to see where stem cells go, because a rat spinal cord is so much smaller ...

Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer

... Acepromazine is widely used as a sedative in horses. It serves as a tranquilizer to better facilitate handling of these large mammals before transportation or surgical procedures. Acepromazine has been classified by the Association of Racing Commissioners International, Inc. as a ...

Getting Started with MicroRNA Research

... by miRNA molecules [1]. Genes encoding approximately 230 miRNAs have already been identified in mammals [2]. Interestingly, more than 90% of the miRNAs are completely conserved among species, suggesting that ...

Principles and applications of electrical cell fusion

... Cloning mammals The famous case of Dolly, the ... carried through the full gestation period. Cloning mammals from embryonic cells was carried out as long ago as the late ...

Principles and applications of electrical cell fusion

... Cloning mammals The famous case of Dolly, the ... carried through the full gestation period. Cloning mammals from embryonic cells was carried out as long ago as the late ...

Transgenic Animals

... or gene constructs derived from other species or not normally found in the host animal. For this reason, mice, rats or other small mammals are used to introduce foreign DNA into oocytes or embryos (blastocysts). Two different ...